Management of antiretroviral drug toxicity;Manejo de la toxicidad por fármacos antirretrovirales

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue 7, 2011, Pages 535-544

  Domingo, Pere ^a   Lozano, Fernando ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Adherence; Antiretroviral therapy; Early toxicity; Long term toxicity; Toxicogenetics

Indexed keywords

ANTIRETROVIRUS AGENT;

CHRONIC TOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; PATIENT COMPLIANCE; REVIEW; TOXICOGENETICS; TREATMENT FAILURE;

EID: 79961030494     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2010.12.001     Document Type: Article

References (65)

1. D'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS AIDS. 2000;14:499-507.
2. Hawkins T. Understanding and managing the adverse effects of antirretroviral therapy. Antivir Res. 2010;85:201-9.
3. Antón P, Soriano V, Jiménez-Nácher I, Rodriguez-Rosado R, Dona MC, Barreiro PM, et al. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. AIDS. 1999;13:524-5.
4. Murphy R, Montaner J, Nevirapine:. A review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs. 1996;5:1183-99.
5. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603-14. (Pubitemid 33063588)
6. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34:1137-42. (Pubitemid 34289688)
7. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-79.
8. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407-14. (Pubitemid 37444469)
9. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714-21.
10. Hawkins T, Geist C, Young B, Giblin A, Mercier RC, Thornton K, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005;6:187-96. (Pubitemid 41601130)
11. Fumaz CR, Muñoz-Moreno JA, Moltó J, Negredo E, Ferrer MJ, Sirera G, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005;38:560-5. (Pubitemid 40524478)
12. Haas D, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-400. (Pubitemid 40065906)
13. Gutiérrez-Valencia A, Viciana P, Palacios R, Ruiz-Valderas R, Lozano F, Terrón A, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events. A randomized trial. Ann Intern Med. 2009;151:149-56.
14. Soriano V, Puoti M, Garcia-Gascó P, Rockstroh JK, Benhamou Y, Barreiro P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1-13. (Pubitemid 350301936)
15. Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182-9. (Pubitemid 34032559)
16. Maida I, Nuñez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr. 2006;42:177-82. (Pubitemid 43884712)
17. Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: A Nested Case-Control Study. Clin Infect Dis. 2009;49:626-35.
18. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus (HCV). 2007 updated recommendations from the HIV-HCV International Panel. AIDS. 2007;21:1073-89.
19. Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192:1381-6. (Pubitemid 41401151)
20. Falcó V, Rodríguez D, Ribera E, Martínez E, Miró JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002;34:838-46. (Pubitemid 34194856)
21. Pedrol E, Ribell M, Deig E, Villà MC, Miró O, Garrabou G, et al. Tratamiento de la hiperlactatemia sintomática y de la acidosis láctica en pacientes con infección por el virus de la inmunodeficiencia humana en tratamiento con inhibidores de la transcriptasa inversa análogos de los nucleósidos. Med Clin (Barc). 2005;125:201-4. (Pubitemid 41153545)
22. Dalakas MC. Peripheral neuropathy and antirretroviral drugs. Peripher Nerv Syst. 2001;6:14-20.
23. Keswani SC, Pardo CA, Cherry CL, Hoke A, McArthur JC. HIV-associated sensory neuropathies. AIDS. 2002;16:2105-17. (Pubitemid 35387264)
24. Simpson D, McArthur J, Olney R, Clifford D, So Y, Ross D, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003;60:1508-14. (Pubitemid 36554814)
25. Valcour V, Yeh TM, Bartt R, Clifford D, Gerschenson M, Evans SR, et al. Acetyl-lcarnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Med. 2009;10:103-10.
26. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1-RNA. AIDS. 2001;15:1517-26. (Pubitemid 32744599)
27. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis. 2002;185:1251-60. (Pubitemid 34439132)
28. Lafeuillade A, Clumeck N, Mallolas J, et al. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study. HIV Clin Trials. 2003;4:37-43. (Pubitemid 36336096)
29. Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005;19:917-25. (Pubitemid 40834934)
30. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383-9. (Pubitemid 34722070)
31. Tebas P, Yarasheski K, Henry K, et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004;20:589-94. (Pubitemid 38813655)
32. Estrada V, De Villar N, Larrad MT, Lopez AG, Fernandez C, Serrano-Rios M. Long-term metabolic consequences of switiching from protease inhibitors to efavirenz in therapy forhumanimmunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis. 2002;35:69-76. (Pubitemid 34666862)
33. Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19:1051-8. (Pubitemid 40961145)
34. Rachlis A, Becker S, Gill J, et al. Successful substitution of protease inhibitors with SUSTIVA (efavirenz) in patients with undetectable plasma HIV-1 RNA levels: results of a prospective, randomized, multicenter, open label study(DMP 266-049) [abstract 475]. En: Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology; 2000.
35. Katlama C, Staszewski S, Cluck N, et al. Successful substitution of protease inhibitors with Sustiva (efavirenz) in patients with undetectable plasma HIV-1 RNA: results of a prospective, randomized, multicenter, open label study (DMP 006-027) [abstract LbPeB7044]. En: Programs and abstracts of the 13th International Conference on AIDS (Durban, South Africa). Rome: International AIDS Society; 2000. p. 283.
36. Martinez E, Romeu J, Garcia-Viejo A, et al. An open randomized study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1-infected patients with lipodystrophy [abstract 668]. En: Programs and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health; 2001.
37. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr. 2001;27:229-36. (Pubitemid 32661963)
38. Barreiro P, Soriano V, Blanco F, Casimiro C, De la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under longterm successful triple combination therapy. AIDS. 2000;14:807-12. (Pubitemid 30303457)
39. Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label multicentre study. AIDS. 2001;15:1811-22. (Pubitemid 32939242)
40. Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036-46. (Pubitemid 37087618)
41. Domingo P, Labarga P, Palacios R, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS. 2004;18:1745-8.
42. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201. (Pubitemid 38917996)
43. Moyle G, Sabin C, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-50. (Pubitemid 44611057)
44. Moyle GJ, Baldwin C, Mandalia S, Comitis S, Burn P, Gazzard B. Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: single arm observational cohort. J Acquir Immune Defic Syndr. 2001;28:399-401. (Pubitemid 33101296)
45. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002;41:1195-211. (Pubitemid 35398692)
46. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417-26.
47. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17-24.
48. Costagliola D, Lang S, Mary-Krause M, Boccara F. Abacavir and cardiovascular risk: reviewing the evidence. Curr HIV/AIDS Rep. 2010;7:127-33.
49. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-524.
50. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23:1841-9.
51. Giralt M, Domingo P, Villarroya F. Lipodystrophy associated with highly active antiretroviral therapy for HIV infection: the adipocyte as a tar get of antiretroviral-induced mitochondrial toxicity. Trends Pharmacol Sci. 2005;26:88-93. (Pubitemid 40170171)
52. Gutierrez M, Mateo G, Domingo P. Strategies in the treatment of HIV-1-associated adipose redistribution syndromes. Expert Opinion Pharmacother. 2007;12:1871-84. (Pubitemid 47321522)
53. Slama L, Lanoy E, Valantin MA, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther. 2008;13:67-76. (Pubitemid 351541675)
54. McComsey GA, Walker UA, Budhathoki CB, et al. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS. 2010;24:2507-15.
55. Domingo P, Knobel H, Guierrez F, Barril G, Fulladosa X. Valoración y manejo de la nefropatía en el paciente con infección por VIH-1: Una revisión práctica. Enferm Infecc Microbiol Clin. 2010;28:185-98.
56. Wever K, Van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55:78-81.
57. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36:S101-105.
58. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963-72.
59. Worm SW, Friis-Møller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010;24:427-35.
60. Liang D, Breaux K, Rodriguez-Barradas M, et al. Allopurinol increases didanosine (ddI) absorption in HIV-infected patients [abstract #A-498]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois.
61. Martinez E, Collazos J, Mayo J, Blanco MS. Sexual dysfunction with protease inhibitors. Lancet. 1999;353:810-1. (Pubitemid 29110412)
62. Bruckert E, Giral P, Heshmati HM, et al. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther. 1996;21:89-94. (Pubitemid 26201741)
63. Merry C, Barry MG, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS. 1999;13:F101-107.
64. Langtry HD, Markham A, Sildenafil:. A review of its use in erectile dysfunction. Drugs. 1999;57:967-89.
65. Vidal F, Gutierrez F, Gutierrez MM, et al. Pharmacogenetics of adverse effects due to antiretroviral treatments. AIDS Rev. 2010;12:15-30.